ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1569 • 2019 ACR/ARP Annual Meeting

    Poor Long-term Renal Outcome in Systemic Lupus Erythematosus Without Abnormal Urinalysis: A Possible Link with Silent Lupus Nephritis

    Hironari Hanaoka1, Jun Kikuchi 2, Shuntaro Saito 1, Hiroshi Takei 3, Kazuoto Hiramoto 1, Tatsuhiro Oshige 1, Noriyasu Seki 4, Hideto Tsujimoto 4, Yuko Kaneko 1 and Tsutomu Takeuchi 5, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, 2Keio Universitiy School of Medicine, Tokyo, Japan, 3Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, 4Mitsubishi Tanabe Pharma Corporation Sohyaku, Tokyo, 5Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: Background/Purpose: It has been well investigated that patients with lupus nephritis (LN) have worse prognosis than those without. Recently reported, about 20% of SLE…
  • Abstract Number: 1570 • 2019 ACR/ARP Annual Meeting

    Can the Montreal Cognitive Assessment (MoCA) Improve the Automated Neuropsychological Assessment Metrics (ANAM) Performance in Screening for Cognitive Impairment in Lupus Patients?

    Oshrat Tayer-Shifman1, Robin Green 2, Dorcas Beaton 3, Lesley Ruttan 2, Joan Wither 4, Maria Tartaglia 5, Mahta Kakvan 1, Sabrina Lombardi 2, Nicole Anderson 1, Jiandong Su 1, Dennisse Bonilla 1, Moe Zandy 1, May Choi 6, Marvin Fritzler 6 and Zahi Touma 7, 1University Health Network, University of Toronto, Toronto, ON, Canada, 2University Health Network, Toronto, ON, Canada, 3St. Michael's Hospital, Toronto, ON, Canada, 4University Health Network, Krembil Research Institute, Toronto, ON, Canada, 5University Health Network, University of Toronto, Toronto, ON, Canada, 6Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 7University Health Network, University of Toronto, Toronto, Canada

    Background/Purpose: : In a related study, we have shown evidence to support the validity of the Automated Neuropsychological Assessment Metrics (ANAM) for the screening of…
  • Abstract Number: 1571 • 2019 ACR/ARP Annual Meeting

    Validity Evidence Supports the Use of Automated Neuropsychological Assessment Metrics (ANAM) as a Screening Tool for Cognitive Impairment in Patients with Systemic Lupus Erythematosus

    Oshrat Tayer-Shifman1, Robin Green 2, Dorcas Beaton 3, Lesley Ruttan 2, Joan Wither 4, Maria Tartaglia 5, Mahta Kakvan 1, Sabrina Lombardi 2, Nicole Anderson 1, Jiandong Su 1, Dennisse Bonilla 1, Moe Zandy 1, May Choi 6, Marvin Fritzler 6 and Zahi Touma 7, 1University Health Network, University of Toronto, Toronto, ON, Canada, 2University Health Network, Toronto, ON, Canada, 3St. Michael's Hospital, Toronto, ON, Canada, 4University Health Network, Krembil Research Institute, Toronto, ON, Canada, 5University Health Network, University of Toronto, Toronto, ON, Canada, 6Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 7University Health Network, University of Toronto, Toronto, Canada

    Background/Purpose: Cognitive impairment (CI) is highly prevalent in Systemic Lupus Erythematosus (SLE). Screening for CI in SLE may be delayed, if relying on the American…
  • Abstract Number: 1572 • 2019 ACR/ARP Annual Meeting

    Persistent Cognitive Impairment in Lupus Patients over 1 Year and Associated Factors

    Dorcas Beaton 1, Robin Green 2, Lesley Ruttan 2, Joan Wither 3, Oshrat Tayer-shifman4, Maria Tartaglia 5, Mahta Kakvan 4, Nicole Anderson 4, Jiandong Su 4, Moe Zandy 4, May Choi 6, Marvin Fritzler 6 and Zahi Touma 4, 1St. Michael's Hospital, Toronto, ON, Canada, 2University Health Network, Toronto, ON, Canada, 3University Health Network, Krembil Research Institute, Toronto, ON, Canada, 4University Health Network, University of Toronto, Toronto, ON, Canada, 5University Health Network, University of Toronto, Toronto, ON, Canada, 6Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

    Background/Purpose: Cognitive impairment (CI) is a common manifestation of systemic lupus erythematosus (SLE) and its course may change over time. The objective was to determine…
  • Abstract Number: 1573 • 2019 ACR/ARP Annual Meeting

    Incidence and Predictors of Atherosclerotic Vascular Events in a Multicentre Inception SLE Cohort

    Murray Urowitz1, Dafna Gladman 2, Jiandong Su 1, Vernon Farewell 3, Jorge Sanchez-Guerrero 4, Juanita Romero-Diaz 5, Sang-Cheol Bae 6, Paul Fortin 7, Ola Nived 8, Ann E Clarke 9, Sasha Bernatsky 10, Caroline Gordon 11, John Hanly 12, Daniel J Wallace 13, David A Isenberg 14, Anisur Rahman 15, Joan Merrill 16, Ellen M Ginzler 17, Graciela Alarcon 18, Michelle Petri 19, Ian Bruce 20, Munther A Khamashta 21, Cynthia Aranow 22, Susan Manzi 23, MA Dooley 24, Rosalind Ramsey-Goldman 25, Andreas Jönsen 8, Kristjan Steinsson 26, Asad Zoma 27, Guillermo Ruiz-Irastorza 28, S Sam Lim 29, Kenneth C Kalunian 30, Murat Inanc 31, Ronald van Vollenhoven 32, Manuel Ramos 33, Diane Kamen 34, Soren Jacobsen 35, Christine Peschken 36, Anca Askanase 37 and Thomas Stoll 38, 1University Health Network, University of Toronto, Toronto, ON, Canada, 2Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, 3University of Cambridge, Cambridge, United Kingdom, 4Toronto Western Hospital, Toronto, ON, Canada, 5Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico, 6Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 7Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, 8Lund University, Lund, Sweden, 9University of Calgary, Calgary, AB, Canada, 10Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 11University of Birmingham, Birmingham, United Kingdom, 12Queen Elizabeth II Health Science Centre (Nova Scotia Rehab Site), Halifax, NS, Canada, 13Cedars-Sinai Medical Centre, Beverly Hills, CA, 14Centre for Rheumatology, London, United Kingdom, 15University College London, London, United Kingdom, 16Oklahoma Medical Research Foundation, Oklahoma City, 17State University of New York Downstate Medical Center, Brooklyn, NY, 18The University of Alabama at Birmingham, Birmingham, AL, 19Johns Hopkins University School of Medicine, Baltimore, MD, 20University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, 21King's College London School of Medicine, London, United Kingdom, 22Feinstein Institute for Medical Research, Manhasset, NY, 23Allegheny Health Network, Pittsburg, PA, 24UnC Kidney Centre, Chapel Hill, NC, 25Northwestern University, Chicago, IL, 26Landspitali, University Hospital, Reykjavik, Iceland, 27Lanarkshire Centre for Rheumatology, Hairmyres Hospital, East Kilbride, Scotland, United Kingdom, 28Unidad de Enfermedades Autoinmunes, BioCruces Health Research Institute, Bizkaia, Spain, 29Emory University, Atlanta, GA, 30UC San Diego School of Medicine, LaJolla, CA, 31Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 32Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, the Netherlands, Amsterdam, Netherlands, 33Department of Internal Medicine, Hospital Nuestra Señora del Prado, Talavera, Talavera, Spain, Talavera, Spain, 34Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC, 35Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark, 36University of Manitoba, Winnipeg, Canada, 37Columbia University Medical Center, New York, NY, 38University of Glasgow, Kilbride, Scotland, United Kingdom

    Background/Purpose: The prevalence of atherosclerotic vascular events (AVE) in published literature of an inception cohort with SLE is 10%. We aimed to investigate the accrual…
  • Abstract Number: 1574 • 2019 ACR/ARP Annual Meeting

    Causes of Death in SLE: Analysis of Inpatient Death from 2000-2018 in a Tertiary Care Hospital in India

    Sarit Sekhar Pattanaik1, Hafis Muhammed 2, Amita Aggarwal 3, Able Lawrence 4, Vikas Agarwal 2, Durga P Misra 2, Latika Gupta 4 and Ramnath Misra 4, 1Sanjay Gandhi post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, 2SGPGI, Lucknow, Uttar Pradesh, India, 3Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India, 4Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, Uttar Pradesh, India

    Background/Purpose: Mortality in Systemic lupus erythematosus (SLE) has reduced over the years but it is still two to three folds as compared to general population.…
  • Abstract Number: 1575 • 2019 ACR/ARP Annual Meeting

    Lymphocyturia Is a Good and Cheap Biomarker for Active Lupus Nephritis and Is Sensitive to Change

    Sarit Sekhar Pattanaik1, Ankita Singh 2, Shilpa Venkataraman 3, Ramnath Misra 4, Vinita Agrawal 2 and Amita Aggarwal 5, 1Sanjay Gandhi post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, 2Sanjay Gandhi Post Graduate institute of medical science, Lucknow, India, Lucknow, Uttar Pradesh, India, 3Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India, 4Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, Uttar Pradesh, India, 5Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India

    Background/Purpose: Multiple urinary biomarkers have been described for lupus nephritis, however none has reached the clinic due to either complex methodology or low discriminatory power.…
  • Abstract Number: 1576 • 2019 ACR/ARP Annual Meeting

    Prevalence and Outcome of Thrombocytopenia in Systemic Lupus Erythematosus – Single Centre Cohort Analysis

    Tatiana Costa Pires1, Raquel Caparrós-Ruiz 2 and David A Isenberg 3, 1Serviço de Medicina 1, Centro Hospitalar de Leiria, Leiria, Portugal, 2UGC de Reumatologia, Instituto de Investigación Biomédica de Málaga, Hospital Universitario de Málaga, Universidad de Málaga, Málaga, Spain, 3Centre for Rheumatology, London, United Kingdom

    Background/Purpose: To characterize the frequency of thrombocytopenia in SLE and determine its time of onset during the course of the disease, severity and impact on mortality.Methods: This…
  • Abstract Number: 1577 • 2019 ACR/ARP Annual Meeting

    The Impact of the New American College of Cardiology/American Heart Association Definition of Hypertension on Cardiovascular Events in Systemic Lupus Erythematosus

    Konstantinos Tselios1, Dafna Gladman 2, Jiandong Su 3 and Murray Urowitz 4, 1University Health Network, University of Toronto, Toronto, 2Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, 3University Health Network, University of Toronto, Toronto, ON, Canada, 4University Health Network, University of Toronto, Toronto, Canada

    Background/Purpose: The 2017 guidelines by the American College of Cardiology/American Heart Association (ACC/AHA) define hypertension at a threshold of ≥130/80mmHg for the systolic and diastolic…
  • Abstract Number: 1578 • 2019 ACR/ARP Annual Meeting

    Factors Implicated in the Development of Early Osteonecrosis in Systemic Lupus Erythematosus

    Konstantinos Tselios1, Dafna Gladman 2, Jiandong Su 3 and Murray Urowitz 3, 1University Health Network, University of Toronto, Toronto, 2Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, 3University Health Network, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Osteonecrosis (ON) complicates approximately 15-20% of patients with systemic lupus erythematosus (SLE) on an average of six years after diagnosis. However, a small subgroup…
  • Abstract Number: 1579 • 2019 ACR/ARP Annual Meeting

    Presence of Antiphospholipid Antibodies in Patients with SLE and Venous Thromboembolic Events of African American and Caucasian Race

    Elena Gkrouzman1, Julia Davis-Porada 1, Mary Peng 2 and Kyriakos Kirou 2, 1Hospital for Special Surgery, New York, 2Hospital for Special Surgery, New York, NY

    Background/Purpose: Risk of thrombosis is elevated in patients with systemic lupus erythematosus (SLE) compared to healthy individuals, especially during the first year after diagnosis. The…
  • Abstract Number: 1580 • 2019 ACR/ARP Annual Meeting

    Development of Comorbidity in Danish Nationwide Cohort of Newly Diagnosed Patients with Systemic Lupus Erythematosus

    Renata Hansen1, Titilola Falasinnu 2, Julia Simard 3, Mikkel Faurschou 4 and Søren Jacobsen 5, 1Copenhagen Lupus and Vasculitis Clinic, Denmark, Stanford, CA, 2Department of Health Research and Policy, Stanford School of Medicine, Palo Alto, CA, 3Stanford University School of Medicine, Palo Alto, CA, 4Copenhagen Lupus and Vasculitis Clinic, Denmark, Copenhagen, Hovedstaden, Denmark, 5Copenhagen Lupus and Vasculitis Clinic, Denmark, Copenhagen, Denmark

    Background/Purpose: Development of comorbidity over time in patients with systemic lupus erythematosus (SLE) is not well characterized. To provide a detailed and comprehensive picture hereof,…
  • Abstract Number: 1581 • 2019 ACR/ARP Annual Meeting

    Impact of Diabetes on Risk of End Stage Renal Disease in Danish Nationwide Cohort of Newly Diagnosed Patients with Systemic Lupus Erythematosus

    Renata Hansen1, Julia Simard 2, Mikkel Faurschou 3, Søren Jacobsen 4 and Titilola Falasinnu 5, 1Copenhagen Lupus and Vasculitis Clinic, Denmark, Stanford, CA, 2Stanford University School of Medicine, Palo Alto, CA, 3Copenhagen Lupus and Vasculitis Clinic, Denmark, Copenhagen, Hovedstaden, Denmark, 4Copenhagen Lupus and Vasculitis Clinic, Denmark, Copenhagen, Denmark, 5Department of Health Research and Policy, Stanford School of Medicine, Palo Alto, CA

    Background/Purpose: Risk of end stage renal disease (ESRD) is increased in patients with systemic lupus erythematosus (SLE). Due to lifestyle –related risk factors, inflammation, and…
  • Abstract Number: 1582 • 2019 ACR/ARP Annual Meeting

    The Association of Lupus Nephritis Histopathologic Classification with Venous Thromboembolism Is Modified by Age at Biopsy

    Ian Cooley1, Vimal Derebail 1, Keisha Gibson 1, Carolina Alvarez 2, Caroline Poulton 1, Lauren Blazek 1, Andrew Love 1, Susan Hogan 1, Ronald Falk 1 and Saira Sheikh 3, 1University of North Carolina at Chapel Hill, Chapel Hill, 2University of North Carolina at Chapel Hill Thurston Arthritis Research Center, Chapel Hill, NC, 3University of North Carolina, Chapel Hill, NC

    Background/Purpose: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that is associated with an increased incidence of venous thromboembolism (VTE). Lupus nephritis (LN) has…
  • Abstract Number: 1583 • 2019 ACR/ARP Annual Meeting

    Prognostic Value of Urinary Biomarkers for the Developing of End Stage Renal Disease in Patients with Systemic Lupus Erythematosus

    Jose A Gómez-Puerta1, Tomás Urrego 2, Blanca Ortiz Reyes 3, Adriana Vanegas-García 4, Carlos H Muñoz-Vahos 4, Luis A González 4 and Gloria Vasquez 5, 1Rheumatology Department, Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, 2Grupo de Inmunología Celular e Inmunogenética, Universidad de Antioquia, Medellín, Antioquia, Colombia, 3Grupo de Inmunología Celular e Inmunogenética, Facultad de Medicina, Universidad de Antioquia, Medellín, Antioquia, Colombia, 4Grupo de Reumatología, Universidad de Antioquia, Medellín, Antioquia, Colombia, 5University of Antioquia, Medellin, Antioquia, Colombia

    Background/Purpose: Background: There is an increasing knowledge about the utility of urinary biomarkers for the diagnosis of lupus nephritis (LN) in patients with systemic lupus…
  • « Previous Page
  • 1
  • …
  • 861
  • 862
  • 863
  • 864
  • 865
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology